Loading...
XKRX
241820
Market cap2mUSD
Mar 21, Last price  
302.00KRW
Name

PCL Inc

Chart & Performance

D1W1MN
No data to show
P/E
—
P/S
2.90
EPS
—
Div Yield, %
—
Shrs. gr., 5y
13.93%
Rev. gr., 5y
103.38%
Revenues
1.25b
-85.22%
243,021,670588,753,931506,144,648128,540,94535,811,00053,682,669,58746,147,521,83737,217,226,6638,429,532,3001,246,175,920
Net income
-52.34b
L+157.60%
-1,864,165,773-2,340,583,841-3,869,221,755-5,771,236,510-7,965,850,46919,508,749,390-31,669,318,653-4,017,547,977-20,317,923,680-52,338,959,350
CFO
-15.78b
L+220.89%
-1,847,089,729-2,455,158,111-3,622,436,613-5,857,074,550-5,120,499,351-2,286,705,821-16,224,740,219-995,049,542-4,916,651,196-15,776,822,560

Profile

PCL, Inc. provides multiplex in vitro diagnostic (IVD) products and platform services. The company offers multiplex antibody and antigen diagnostic kits for the detection of antibodies to human immunodeficiency virus (HIV) 1 and 2, HBV, hepatitis C virus (HCV), and human T-lymphotropic virus 1 and 2, as well as antigens to HIV p24, HCV core, and HBV surface in human serum or plasma. It also provides Ai, an influenza A/B typing rapid diagnostic test kit; Cancer6, a multiple tumor markers screening kit; and sciLINER LATERAL FLOW DISPENSER, a dispenser for membrane materials with active visual drop volume control. In addition, the company offers platform services, such as sol-gel spotting service that immobilizes the customer's requested material using the SolB reagent; and SG ID service, which provides customers with a molecule of interest immobilized in the SolB reagent and identified. PCL, Inc. is headquartered in Seoul, South Korea.
URL
http://www.pclchip.com
IPO date
Feb 23, 2017
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
1,246,176
-85.22%
8,429,532
-77.35%
37,217,227
-19.35%
Cost of revenue
22,053,313
17,670,167
43,240,152
Unusual Expense (Income)
NOPBT
(20,807,137)
(9,240,635)
(6,022,925)
NOPBT Margin
Operating Taxes
(505)
(81,441)
6,312
Tax Rate
NOPAT
(20,806,632)
(9,159,194)
(6,029,238)
Net income
(52,338,959)
157.60%
(20,317,924)
405.73%
(4,017,548)
-87.31%
Dividends
Dividend yield
Proceeds from repurchase of equity
24,004,997
23,305,425
12,271,607
BB yield
-74.25%
-16.01%
-6.95%
Debt
Debt current
8,288,830
15,634,422
25,976,612
Long-term debt
3,357,288
4,084,446
5,205,583
Deferred revenue
10
Other long-term liabilities
593,398
552,813
1,208,776
Net debt
3,002,799
(11,510,889)
(14,285,454)
Cash flow
Cash from operating activities
(15,776,823)
(4,916,651)
(995,050)
CAPEX
(127,800)
(3,259,165)
(2,808,174)
Cash from investing activities
(4,452,998)
(3,844,938)
(20,905,892)
Cash from financing activities
15,288,762
(10,364,074)
9,238,752
FCF
1,162,095
(15,137,438)
(10,460,368)
Balance
Cash
3,957,826
11,802,825
32,467,651
Long term investments
4,685,493
19,426,932
12,999,998
Excess cash
8,581,010
30,808,281
43,606,788
Stockholders' equity
(82,600,189)
(31,964,155)
(30,993,796)
Invested Capital
101,298,010
89,408,106
96,617,803
ROIC
ROCE
EV
Common stock shares outstanding
58,355
40,615
35,429
Price
554.00
-84.55%
3,585.00
-28.06%
4,983.33
-57.95%
Market cap
32,328,909
-77.80%
145,605,083
-17.53%
176,552,380
-56.25%
EV
35,331,708
136,214,151
164,352,835
EBITDA
(18,245,043)
(6,375,274)
(3,436,895)
EV/EBITDA
Interest
1,202,139
2,496,338
4,220,249
Interest/NOPBT